



# China's biopharma innovation: Going global and achieving commercial breakthroughs



Global cumulative count of ongoing innovative drug projects (up to 2024)



# Weekly Facts & Figures.


- **Global drug deals:** License-outs jumped from 5 in 2019 to 94 in 2024, worth USD 51.9B.
- **Pipeline leadership:** China leads with 3,575 active innovative drug projects.
- **Market boost:** In 2025, the Wind Drug Index rose 20%, Hang Seng Healthcare ETF up 40%.

# What This Means.

"China's biopharma is no longer catching up—it's breaking through. Backed by strong policy and booming global deals, the industry is now setting the pace worldwide."



**Weiqing Zhu**  
Consultant



**Follow us & activate the bell to never miss  
a Sinolytics Radar again!**



**Discover more insights and services:  
Visit [www.sinolytics.de](http://www.sinolytics.de)**